PDSB News and Press, PDS Biotechnology Corporation From 08/13/23

2023-08-13 05:30:32 ET Summary PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the h...

PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating plat...

PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating plat...

Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA ® for recurrent or metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nas...

FLORHAM PARK, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® ...

Composition of matter and use patent for Versamune ® in combination with PDS0301 allowed in Canada PDS Biotech’s proprietary combination of Versamune ® based PDS0101 and PDS0301 with an immune checkpoint inhibitor resulted in 21 months median overall survival in a...

FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today its expected addition to the broad-market Russell 2000 ® ...

2023-06-14 09:12:07 ET PDS Biotechnology Corporation ( NASDAQ: PDSB ) announced Wednesday that Stage two of its Phase 2 trial for its lead asset PDS0101 in head and neck cancer reached the efficacy threshold with Merck’s ( NYSE: MRK ) anti-PD-1 therapy, Keytruda. ...

14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed objective response Efficacy and safety continue to be monitored as additional patients have ye...

2023-06-06 09:49:10 ET Following a ~31% decline in the previous session, the shares of PDS Biotechnology ( NASDAQ: PDSB ) rose ~9% in the pre-market Tuesday as Cantor Fitzgerald and H.C. Wainwright defended the stock arguing that the selloff was overdone. H.C. Wainwright analyst...